One of the harsh realities of the equities arena is that it’s open and entropic. In other words, exogenous factors could come ...

Eli Lilly & Co. is tapping the US investment-grade debt market with a deal that’s expected to include a 40-year bond, a ...

Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

The company says broad tariffs would raise costs, limit patient access and undermine domestic manufacturing. Eli Lilly is sounding a warning on proposed tariffs on pharmaceuticals, saying it would ...

Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...

The deal allows Eli Lilly and Company (NYSE:LLY) to have exclusive rights to develop and commercialize drug candidates ...

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

To provide a brief background, the TRAILBLAZER-ALZ 2 LTE study was a Phase 3, double-blind extension of the original ...

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...

Texas Attorney General Ken Paxton has sued Eli Lilly, alleging the drugmaker offered illegal incentives to providers, leading ...